Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Varsha Gandhi, PhD, on Ibrutinib

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jan
13
Today In Oncology
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer
Anaplastic Glioma Concurrent vs Adjuvant Temozolomide
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer
Refractory LBCL CD19-Targeting CAR T-Cell Therapy Plus Rituximab
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo